Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension

A Randomized, Double-blind, Double-dummy, Multi-center Study to Investigate the Safety and Efficacy of Olmesartan Medoxomil Compared With Losartan Potassium in Patients With Mild to Moderate Essential Hypertension

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00856271

Enrollment

287

Registered

2009-03-05

Start date

2004-08-31

Completion date

2005-04-30

Last updated

2010-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension

Brief summary

The purpose of this study is to evaluate the efficacy and safety of olmesartan medoxomil compared with losartan potassium in patients with mild to moderate essential hypertension.

Interventions

DRUGolmesartan medoxomil

oral tablets, once daily for 8 weeks

DRUGlosartan potassium

capsules, once daily for 8 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* mild to moderated essential hypertension (mean seated diastolic blood pressure ≥ 95 mmHg and \<110 mmHg, mean seated systolic blood pressure \< 180 mmHg) * able to give written informed consent

Exclusion criteria

* known or suspected secondary hypertension * history of chronic hepatic diseases * obstructive hypertrophic cardiomyopathy/clinically significant valvular heart disease * cardiac arrhythmia * unstable angina pectoris * congestive heart insufficiency (New York Heart Association classification III-IV) * bilateral renal artery stenosis * isolated renal artery stenosis * post renal transplantation * history of acute myocardial infarction/percutaneous transluminal coronary angioplasty or heart surgery within three months before enrollment * retina bleeding/effusion * insulin dependent diabetes mellitus * uncontrolled non-insulin dependent diabetes mellitus

Design outcomes

Primary

Measure	Time frame
Change of trough seated diastolic blood pressure from baseline to 8 weeks	Baseline to 8 weeks

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026